Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3554 participants.
Also called NCT02892149
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 3,554 participants
- Sponsor
- Registry
-
NCT02892149 -
2016-001360-11
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Brazil, Bulgaria, Canada, France, Germany, Israel, Italy, Mexico, Poland, Portugal, Russia, Serbia, South Korea, Ukraine, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02892149. Randomized; no masking; primary purpose treatment. Start 2016-08 (actual); primary completion 2020-01-16 (actual). Results posted on 2022-06-28.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)
- Condition
- Anemia
- Condition
- Dialysis-Dependent Chronic Kidney Disease
- Intervention (Drug)
- Vadadustat
- Intervention (Drug)
- Darbepoetin alfa
- Lead sponsor
- Akebia Therapeutics
Record details
- Record id
cardio:ct-nct02892149- Content hash
35d149ed3f9a413e0bb1e44b95cbc2d9ca28e6f05de91d9cd6c1a73c4941f599